(esomeprazole, dexlansoprazole [DEXILANT], omeprazole, omeprazole and sodium bicarbonate [ZEGERID], lansoprazole, pantoprazole
, rabeprazole, esomeprazole and naproxen [VIMOVO]; PRILOSEC OTC
, ZEGERID OTC
, PREVACID 24-HR; and all other generic counterparts).
We petitioned the FDA to require the inclusion of black box warnings identifying the following risks: rebound acid hypersecretion, which results in dependence on these frequently overused drugs; fracture; infection; and magnesium deficiency.